Press release
Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Epilepsy Research. Learn more about our innovative pipeline today! @ Epilepsy Pipeline Outlook [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Epilepsy Pipeline Report
* In June 2025, Ono Pharmaceutical Co. Ltd announced a Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures.
* In June 2025, UCB Biopharma SRL conducted a study is to evaluate the long-term safety and tolerability of brivaracetam. EP0156 is designed to assess the long-term safety and tolerability of BRV in pediatric study participants with epilepsy who participated in the neonatal study N01349 [NCG03325439] and/or have participated in the open-label, long-term, follow-up pediatric study N01266 [NCT01364597].
* DelveInsight's Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
* The leading Epilepsy Companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
* Promising Epilepsy Pipeline Therapies such as Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin , and others.
Stay informed about the cutting-edge advancements in Epilepsy treatments. Download for updates and be a part of the revolution in Neurology Care @ Epilepsy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Epilepsy Emerging Drugs Profile
* EPX-100: Harmony Biosciences
EPX-100 is a potential new treatment being for people with Dravet syndrome and Lennox-Gastaut Syndrome. EPX-100 is a repurposed antihistamine, which was used in the 1950s and 1960s to treat itchiness. The medication is thought to be able to suppress seizures through its action on the serotonin signaling pathways, a mechanism that is different from its anti-histaminic properties. Serotonin is a chemical messenger present in many parts of the brain. Scientists think that people with Dravet syndrome and Lennox-Gastaut Syndrome may have alterations in the serotonin signaling pathway, but the exact problems are not known. Likewise, precisely how EPX-100 affects serotonin systems in the brain to reduce seizures is still unclear. According to company's pipeline the drug is in the Phase III stage of its development for the treatment of Dravet syndrome and is in the Phase II stage of its development for the treatment of Lennox-Gastaut Syndrome.
* BMB-101: Bright Minds Biosciences
BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests. Compared to Locaserin, BMB-101 exhibits strong Gq signaling coupled with minimal beta-arrestin recruitment. Mechanistically, Serotonin (5- Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behavior and the modulation of behavioral effects of psychostimulants, opioids, alcohol and nicotine. Results of clinical trials and animal studies indicate that 5-HT2C up receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behavior that can escalate compulsive drug use. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Epilepsy.
* STK-001: Stoke Therapeutics
STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Dravet Syndrome.
* NRTX-1001: Neurona Therapeutics
NRTX-1001 inhibitory neurons are targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair the affected neural network. NRTX-1001 is delivered as a single, one-time dose and is intended to persist and provide long-term seizure suppression. In preclinical studies, NRTX-1001 has provided seizure-freedom to the majority of the cell treatment group and has not shown signs of dose-limiting toxicity. The preclinical safety and efficacy data have led to an FDA-cleared Phase I/II clinical trial of NRTX-1001 for drug-resistant temporal lobe epilepsy.
* IAMA-6: IAMA Therapeutics
IAMA-6 is an orally administered small molecule therapeutics designed to directly target and inhibit NKCC1-associated neuronal hyperexcitability. The elevated activity of NKCC1 is implicated in various pathological conditions, underscoring the significant potential of NKCC1 inhibition in the treatment of both idiopathic and secondary forms of autism (autism spectrum disorder, or ASD), refractory epilepsy, Dravet Syndrome, and other neurological disorders. With the capability to be applied across multiple central nervous system (CNS) indications, IAMA-6 has demonstrated its safety and favorable tolerability in pre-clinical studies. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Epilepsy.
The Epilepsy Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
* Epilepsy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.
Learn more about Epilepsy Drugs opportunities in our groundbreaking Epilepsy research and development projects @ Epilepsy Unmet Needs [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Epilepsy Companies
UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
Epilepsy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Epilepsy Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Epilepsy treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Epilepsy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Epilepsy Pipeline Report
* Coverage- Global
* Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
* Epilepsy Pipeline Therapies- Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin , and others.
* Epilepsy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Epilepsy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Epilepsy Pipeline on our website @ Epilepsy Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Epilepsy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Epilepsy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* EPX-100: Harmony Biosciences
* Mid Stage Products (Phase II)
* BMB-101: Bright Minds Biosciences
* Early Stage Products (Phase I)
* IAMA-6: IAMA Therapeutics
* Preclinical and Discovery Stage Products
* NT102: Neuroene Therapeutics
* Inactive Products
* Epilepsy Key Companies
* Epilepsy Key Products
* Epilepsy- Unmet Needs
* Epilepsy- Market Drivers and Barriers
* Epilepsy- Future Perspectives and Conclusion
* Epilepsy Analyst Views
* Epilepsy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epilepsy-pipeline-appears-robust-with-75-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4103593 • Views: …
More Releases from ABNewswire
From Ashes to Light: Masterpieces Reborn
In 2024, renowned Japanese printmaker Kouji Ochiai passed away in a sudden fire, leaving nearly 1,000 hidden works. His son, Yosuke Gifre Ochiai, now seeks to preserve and share these masterpieces through a Kickstarter campaign-honoring his father's legacy while transforming the forgotten studio into a space of healing and inspiration for future generations.
A Lost Father. A Discovered Legacy.
The Life and Prints of Kouji Ochiai [https://www.kickstarter.com/projects/1561310332/from-flames-my-fathers-paintings-whisper-through-time] , Brought to the World…
Arlington-Based Realtor Eric Torres Redefines the Home Buying Experience for Fir …
In the fast-paced world of real estate, Eric Torres, a licensed Realtor based in Arlington, TX, is setting new standards for how first-time homebuyers and sellers navigate one of life's most significant decisions. Serving the DFW Metroplex, including Fort Worth, Mansfield, Grand Prairie, and Bedford, Torres is committed to providing personalized service that paves the way for seamless transactions.
Image: https://www.abnewswire.com/upload/2025/07/16e26585eea91e5dd0518a3687add09a.PNG
Understanding first-time buyers' challenges, Torres champions an approach centered on clear…
Uncommon Gun Reviews Help Gunprime Reach 100K Subscribers
Desert Eagles, Mini Shells, and One Very Surprised UPS Driver
BIRMINGHAM, AL - Gunprime has officially hit 100,000 YouTube subscribers - not with slick production or big marketing budgets, but with unfiltered, off-the-wall gun reviews that somehow keep going viral.
"We never set out to build a YouTube channel," said one team member. "It started as an excuse to get out of the shop and shoot. Then the guys behind the counter…
Party Bus Toronto Redefines Group Travel with Modern Party Bus Rentals in Toront …
Image: https://www.abnewswire.com/upload/2025/07/0fe0fa4584aef249108f350ca5abb8a4.jpg
Whether it is a colorful summer festival, a golden birthday or a memorable wedding party, Toronto is a place where people love to get together and celebrate. And when it comes to the prearrangement of group transportation for such special occasions, party and limo bus companies have been changing the game, providing for such options that make the group experience all the more engaging and fun.
Party buses are luxurious,…
More Releases for Epilepsy
Portable Epilepsy Monitoring Market in 2025
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Portable Epilepsy Monitoring Market- (By Product Type (Device Type (Chest Sensor, Watch Sensor, Monitors, Cameras, Mattresses and Pillows, and Others) and Service), By End User (Hospitals, Ambulatory Surgery Centres & Clinics, Neurology Centres, and Home Care Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global…
Top 10 Epilepsy Companies Analysis (2024)
Epilepsy also known as seizure disorder, is a chronic noncommunicable disease that affects brain. Epilepsy affects people of all races, ethnic backgrounds, genders, and ages.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00016405/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Epilepsy Market are:
• Idexx Laboratories Inc.
• PBD Biotech Ltd
• Thermo Fisher Scientific Inc.
• Innovative Diagnostics SAS
• Neogen Corp
• Enfer Labs
• bioMerieux SA
• Ring Biotechnology Co Ltd
• Bionote Inc.
• Shenzhen Bioeasy Biotechnology Co Ltd.
Contact Us:
If you have any queries about this report or if…
Epilepsy Market: Trends, Opportunities, and Challenges
Epilepsy is a neurological disorder characterized by recurrent seizures, which are caused by abnormal electrical activity in the brain. This condition affects millions of people globally, making it one of the most common neurological disorders. As the global burden of epilepsy increases, the demand for effective treatments and solutions continues to grow. The epilepsy market is evolving rapidly, with advancements in medication, diagnostics, and therapeutic technologies. This guest post aims…
Epilepsy Device Market: for Epilepsy Devices Poised to Exceed $1 Billion by 2031 …
The global epilepsy devices market isx experiencing a remarkable surge, poised to exceed a valuation of $1.1 billion by 2031, as revealed by the latest market analysis. According to the report released by Allied Market Research, the market was valued at $675.23 million in 2021 and is projected to grow at a CAGR of 5.1% from 2022 to 2031.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://www.alliedmarketresearch.com/request-sample/A14821
Epilepsy devices play…
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market - Breaking the Sei …
Newark, New Castle, USA: The "Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market: https://www.growthplusreports.com/report/epilepsy-with-myoclonic-atonic-seizures-therapeutics-market/8029
This…
Rising Instances of Pediatric Epilepsy to Pave Novel Growth Avenues in Epilepsy …
Owing to large scale prevalence of epilepsy cases, inclusive of pediatric epilepsy, the market for epilepsy drugs is likely to remain agile in the coming years. Prevalent amongst both male and female demographics alike, epilepsy is a critical condition that affects the brain both partially as well as in whole. Lucrative reimbursement policies, coupled with growing patient awareness about novel therapeutics are likely to reflect favorably on the growth curve…
